Lupin resumes anti-diabetic drug sales in US after court nod

Published: April 19, 2012

Drug firm Lupin today said, it has resumed sales of generic version of Shionogi’s Fortamet tablets, used in treating diabetes, in the American market after getting clearance from a US Court.

“US Court of Appeals for the Federal Circuit has granted its (Lupin’s) request to stay the preliminary injunction that had earlier barred sales of its generic Shionogi’s Fortamet tablets,” a company official said in a statement.

Related Stories

News Now

-
Markets end on a firm note
-
Centre refuses to take stand on Ram Setu, asks SC to decide
-
Nokia ditches sales chief as smartphone disappoints
-
Gems, jewellery exports decline by 17.69% in March
-
Samsung eyes 25-30% growth in Indian ops this year
More
In December last year, Shionogi’s request for a preliminary injunction had been granted and had blocked Lupin from further sales of the product.

In 2011, Lupin had received the final approval for its generic version from the US Food and Drug Administration and had launched the product in September that year.

Following the court order, the Mumbai-headquartered firm said it has now resumed sales of the product in the US market.

Fortamet is indicated as a supplement to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Citing IMS Health data, the company said annual US sales for Fortamet stood at USD 70.2 million for the twelve months ending December 2011.

Shares of Lupin were trading at Rs 556 on the BSE in afternoon trade, up 0.32 per cent from its previous close.

<!– –>

Other Stories
-
Markets end on a firm note
-
Centre refuses to take stand on Ram Setu, asks SC to decide
-
Nokia ditches sales chief as smartphone disappoints
-
Gems, jewellery exports decline by 17.69% in March
-
Samsung eyes 25-30% growth in Indian ops this year
<!–

More

rr –>

Read Business news in

Lupin resumes anti-diabetic drug sales in US after court nod

Related Posts via Categories

Leave a Reply